UBS has maintained a "Buy" rating for STMicroelectronics, setting a target price of 34 euros. Analyst Francois-Xavier Bouvignies noted the credibility of the semiconductor group's medium-term targets announced during a recent capital market day, while emphasizing the importance of short-term business recovery.
UBS has maintained a "Buy" rating for STMicroelectronics with a target price of 34 euros following a recent capital market day. Analyst Francois-Xavier Bouvignies noted that the company's long-term targets have been postponed from 2027 to 2030, as the market awaits clearer signs of recovery amid current uncertainties.
UBS has maintained a "buy" rating for STMicroelectronics with a target price of 34 euros following a recent capital markets day. Analyst Francois-Xavier Bouvignies noted that the company's long-term targets have been postponed from 2027 to 2030, suggesting the market will await further signs of recovery before embracing these new goals.
UBS has maintained its "Buy" rating for STMicroelectronics, setting a target price of 34 euros. Analyst Francois-Xavier Bouvignies noted that the company's long-term targets have been pushed back to 2030 due to current market uncertainties, leading to a cautious outlook for recovery.
UBS has maintained a "Buy" rating for STMicroelectronics with a target price of 34 euros following a recent capital market day. Analyst Francois-Xavier Bouvignies noted that the company's long-term targets have been postponed from 2027 to 2030, as the market awaits clearer signs of recovery amid current uncertainties.
UBS has maintained a "Buy" rating for STMicroelectronics, setting a target price of 34 euros. Analyst Francois-Xavier Bouvignies noted that the company"s long-term targets have been postponed from 2027 to 2030, as the market awaits clearer signs of recovery amid current uncertainties.
UBS has maintained a "Buy" rating for STMicroelectronics, setting a target price of 34 euros. Analyst Francois-Xavier Bouvignies noted that the company"s long-term goals have been postponed to 2030 due to the current unpredictable market conditions, leading to a cautious outlook for recovery.
The FTSE MIB index has been fluctuating between 33,000 and 35,000 points, with a bullish outlook if it breaks upward, targeting 40,000 points. The potential UniCredit-Commerzbank merger could boost market sentiment, while upcoming macroeconomic data will be crucial for cyclical sectors.
The BioMEMS and microsystem healthcare market is projected to grow from $4.53 billion in 2023 to $8.34 billion by 2028, driven by the demand for personalized medicine and advancements in diagnostic tools. Key players include Johnson & Johnson and Qualcomm, focusing on innovative products like integrated audio modules for hearing aids. Major trends include the integration of AI and the development of lab-on-a-chip technologies for improved diagnostics and treatment.
UBS has maintained a 'Buy' rating for STMicroelectronics, setting a price target of 38 euros. Analyst Francois-Xavier Bouvignies noted that the share price trend is likely to be influenced by significant correction risks for 2025 expectations, with the improved operating result attributed to cost measures.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
